Market Overview:
The global latent tuberculosis infection (LTBI) testing market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of tuberculosis, growing awareness about LTBI testing, and technological advancements in the field of LTBI testing. The tuberculin skin test (TST) segment is expected to dominate the global latent tuberculosis infection (LTBI) testing market during the forecast period. This can be attributed to its low cost and easy availability compared with other tests available for diagnosing LTBI. The interferon gamma released assay (IGRA) segment is projected to grow at a higher CAGR during the forecast period owing to its high accuracy and specificity compared with other tests available for diagnosing LTBI. In terms of application, hospitals and clinics are expected to account for a major share of the global latent tuberculosis infection (LTBI)testing market duringthe forecast period.
 Testing Industry Outlook.svg)
Product Definition:
Latent tuberculosis infection (LTBI) testing is a blood or skin test used to determine if a person has been infected with the tuberculosis (TB) bacteria. The test is important because it can help identify people who are at risk of developing active TB disease in the future.
Tuberculin Skin Test (TST):
The global Tuberculin Skin Test (TST) market size was valued at USD 4.5 billion in 2016 and is expected to grow at a CAGR of XX% over the forecast period. The rising prevalence of tuberculosis, increasing government initiatives for its diagnosis & control, and growing demand for accurate diagnostic tools are some high impact rendering drivers of this market.
Interferon Gamma Released Assay (IGRA):
The Interferon gamma released assay (IGRA) is a new technology that helps detect latent tuberculosis infection in the body. IGRA has been found to be more accurate than the skin test for detection of latent tuberculosis infection. The technique is based on measurement of interferon gamma, a protein hormone produced by the immune system in response to bacteria or virus infections.
Global Interferon Gamma Released Assay (IGRA).
Application Insights:
The others application segment held the largest share of more than 70.0% in 2017. The segment includes home healthcare and overseas clinics/hospitals. Latent tuberculosis infection testing is carried out mostly in hospitals and clinics as it is a cost-effective method compared to diagnostic laboratories, which has resulted in growth of this segment over the recent years.
Hospital based tests are preferred for diagnosis as they offer advantages such as convenience, faster results.
Regional Analysis:
Europe dominated the global market in terms of revenue share in 2017. The presence of well-developed primary, secondary and tertiary care hospitals supported the growth. Moreover, high prevalence of HIV/AIDS and diabetes is expected to drive demand for LTBI testing services over the forecast period. Asia Pacific is estimated to grow at a lucrative CAGR during the forecast period owing to increasing government initiatives for latent tuberculosis infection control programs along with rising awareness about MDR-TB diagnosis & treatment procedures coupled with an increase in healthcare expenditure by private as well as public sectors.
Growth Factors:
- Increasing incidence of tuberculosis (TB)
- Growing awareness about LTBI and its diagnosis and treatment
- Rising demand for point-of-care tests
- Technological advancements in TB diagnostics
- Increasing funding for TB control programs
Scope Of The Report
Report Attributes
Report Details
Report Title
Latent Tuberculosis Infection (LTBI) Testing Market Research Report
By Type
Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA)
By Application
Hospitals and Clinics, Diagnostic Laboratories, Others
By Companies
Qiagen, Sanofi, Oxford Immunotec, Thermo Fisher Scientific, Par Sterile, Bio-Rad Laboratories
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
213
Number of Tables & Figures
150
Customization Available
Yes, the report can be customized as per your need.
Global Latent Tuberculosis Infection (LTBI) Testing Market Report Segments:
The global Latent Tuberculosis Infection (LTBI) Testing market is segmented on the basis of:
Types
Tuberculin Skin Test (TST), Interferon Gamma Released Assay (IGRA)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals and Clinics, Diagnostic Laboratories, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Qiagen
- Sanofi
- Oxford Immunotec
- Thermo Fisher Scientific
- Par Sterile
- Bio-Rad Laboratories
 Testing Market Overview.svg)
Highlights of The Latent Tuberculosis Infection (LTBI) Testing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tuberculin Skin Test (TST)
- Interferon Gamma Released Assay (IGRA)
- By Application:
- Hospitals and Clinics
- Diagnostic Laboratories
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Latent Tuberculosis Infection (LTBI) Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Testing Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Latent tuberculosis infection (LTBI) is a condition in which someone has the TB bacteria but does not have active TB disease. LTBI testing can help identify people who may be at risk for developing active TB disease.
Some of the major companies in the latent tuberculosis infection (ltbi) testing market are Qiagen, Sanofi, Oxford Immunotec, Thermo Fisher Scientific, Par Sterile, Bio-Rad Laboratories.
The latent tuberculosis infection (ltbi) testing market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Latent Tuberculosis Infection (LTBI) Testing Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Latent Tuberculosis Infection (LTBI) Testing Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Latent Tuberculosis Infection (LTBI) Testing Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Latent Tuberculosis Infection (LTBI) Testing Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Latent Tuberculosis Infection (LTBI) Testing Market Size & Forecast, 2020-2028
4.5.1 Latent Tuberculosis Infection (LTBI) Testing Market Size and Y-o-Y Growth
4.5.2 Latent Tuberculosis Infection (LTBI) Testing Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Tuberculin Skin Test (TST)
5.2.2 Interferon Gamma Released Assay (IGRA)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals and Clinics
6.2.2 Diagnostic Laboratories
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Latent Tuberculosis Infection (LTBI) Testing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Latent Tuberculosis Infection (LTBI) Testing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Tuberculin Skin Test (TST)
9.6.2 Interferon Gamma Released Assay (IGRA)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals and Clinics
9.10.2 Diagnostic Laboratories
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Tuberculin Skin Test (TST)
10.6.2 Interferon Gamma Released Assay (IGRA)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals and Clinics
10.10.2 Diagnostic Laboratories
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Tuberculin Skin Test (TST)
11.6.2 Interferon Gamma Released Assay (IGRA)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals and Clinics
11.10.2 Diagnostic Laboratories
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Tuberculin Skin Test (TST)
12.6.2 Interferon Gamma Released Assay (IGRA)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals and Clinics
12.10.2 Diagnostic Laboratories
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Tuberculin Skin Test (TST)
13.6.2 Interferon Gamma Released Assay (IGRA)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals and Clinics
13.10.2 Diagnostic Laboratories
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Latent Tuberculosis Infection (LTBI) Testing Market: Competitive Dashboard
14.2 Global Latent Tuberculosis Infection (LTBI) Testing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Qiagen
14.3.2 Sanofi
14.3.3 Oxford Immunotec
14.3.4 Thermo Fisher Scientific
14.3.5 Par Sterile
14.3.6 Bio-Rad Laboratories
